NICE has rejected a new blood cancer drug, Yescarta, which is for the treatment of non-Hodgkin lymphoma, for NHS use due to the drug being too expensive.
You Can See More: Cancer: Costly non-Hodgkin lymphoma drug rejected for NHS use
The following article Cancer: Costly non-Hodgkin lymphoma drug rejected for NHS use is courtesy of Daily Express :: Health Feed
NICE has rejected a new blood cancer drug, Yescarta, which is for the treatment of non-Hodgkin lymphoma, for NHS use due to the drug being too expensive.
NICE has rejected a new blood cancer drug, Yescarta, which is for the treatment of non-Hodgkin lymphoma, for NHS use due to the drug being too expensive.
Related Posts:
You Can See More: 'Get a test!' The 'wide array' of Covid symptoms to spot as hospital admissions soar- You Can See More: Where free lateral flow tests are available right now
- You Can See More: Damp house? You may be more likely to have respiratory problems - NHS insight
- You Can See More: Gene Simmons: KISS star's blunt tips for living longer - 'Crack is out of the question'
- You Can See More: Heart disease: The best diet shown to help with a ‘37 percent decreased mortality risk’
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.